Aldeyra's eye drug meets main goal in late-stage study, shares surge

Aldeyra Therapeutics Inc said on Tuesday its drug reproxalap to treat a form of allergic reaction to the eye met the main goal in a late-stage trial, sending shares up more than 60 percent.